2013 ACCF/AHA Guideline for the Management of Heart Failure
Рекомендации ACCF/AHA 2013 года по ведению пациентов с сердечной недостаточностью
2013-06-05
SCID: 54.1/fz3bhzjw
Discuss with AI
cardiac resynchronization therapyevidence-based guidelinesheart failure managementimplantable cardioverter-defibrillatorpreserved ejection fraction
Figures from the paper
Abstract (AI)
Introduction 1.1. Methodology and Evidence ReviewThe recommendations listed in this document are, whenever possible, evidence based.An extensive evidence review was conducted through October 2011 and includes selected other references through April 2013.Searches were extended to studies, reviews, and other evidence conducted in human subjects and that were published in English from PubMed, EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports, and other selected databases relevant to this guideline.Key search words included but were not limited to the following: heart failure, cardiomyopathy, quality of life, mortality, hospitalizations, prevention, biomarkers, hypertension, dyslipidemia, imaging, cardiac catheterization, endomyocardial biopsy, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists/blockers, beta blockers, cardiac, cardiac resynchronization therapy, defibrillator, device-based therapy, implantable cardioverterdefibrillator, device implantation, medical therapy, acute decompensated heart failure, preserved ejection fraction, terminal care and transplantation, quality measures, and performance measures.Additionally, the committee reviewed documents related to the subject matter previously published by the ACCF and AHA.References selected and published in this document are representative and not all-inclusive.To provide clinicians with a representative evidence base, whenever deemed appropriate or when published, the absolute risk difference and number needed to treat or harm are provided in the guideline (within tables), along with confidence intervals and data related to the relative treatment effects such as odds ratio, relative risk, hazard ratio, and incidence rate ratio. Organization of the Writing CommitteeThe committee was composed of physicians and a nurse with broad expertise in the evaluation, care, and management of patients with heart failure (HF).The authors included general cardiologists, HF and transplant specialists, electrophysiologists, general internists, and physicians with methodological expertise.The committee included representatives from the ACCF, AHA, American Academy of Family Physicians, American College of Chest Physicians, American College of Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation. 1.3.
Key Findings
1
An extensive literature review through October 2011, supplemented with selected evidence through April 2013, informed the recommendations.
2
Evidence was gathered from PubMed, EMBASE, Cochrane, AHRQ reports, and other relevant databases covering medications, devices, diagnostics, prevention, outcomes, and advanced heart failure care.
3
The guideline provides evidence-based recommendations for evaluating, preventing, and managing heart failure across diverse clinical settings.
4
The multidisciplinary writing committee included cardiologists with broad expertise in heart-failure care and a nurse, supporting comprehensive clinical guidance.
5
When available, recommendations include absolute risk differences, numbers needed to treat or harm, confidence intervals, and relative treatment-effect measures.
Research Object
Heart failure
Research Subject
evidence-based management and care of heart failure, including prevention, diagnosis, treatment, outcomes, and performance measures
Publication Details
Publication Date
2013-06-05
Journal
Publisher
ISSN
Cited by
12673
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 20122012
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines2004
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults2007
Guidelines for the management of atrial fibrillation2010
Forecasting the Future of Cardiovascular Disease in the United States2011
Standards of Medical Care in Diabetes—20122011
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction2007
Statins for the primary prevention of cardiovascular disease2013
Coronary Artery Bypass Surgery With or Without Mitral Valve Annuloplasty in Moderate Functional Ischemic Mitral Regurgitation2012
Cited by13
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2017
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation2014
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients2016
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death2015
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association2013
Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist2014
Clinical Update: Cardiovascular Disease in Diabetes Mellitus2016
Dilated Cardiomyopathy: Genetic Determinants and Mechanisms2017
Calcium Signaling and Cardiac Arrhythmias2017
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z2018
Diagnostic Accuracy of Point-of-Care Lung Ultrasonography and Chest Radiography in Adults With Symptoms Suggestive of Acute Decompensated Heart Failure: A Systematic Review and Meta-analysis2019
Mechanical Circulatory Support in the Treatment of Advanced Heart Failure2017
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes2018